Navigation Links
AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Date:3/6/2009

QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its fourth quarter and full-year 2008 financial and operating results before market open on Wednesday, March 11, 2009. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-646-3095 514-807-8791 or 800-814-4859. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces the ... Offering wavelength scanning from 190 to 1,100 nm, ... in a variety of industries, including environmental, food ... enables intuitive operation, while the enhanced validation, maintenance ...
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... the First Nine Months of 2007 - Continued Strong Organic Growth, With Revenue Up 8.5% ... nine months ended September 30,2007. Consolidated revenue for the first nine months, EUR millions ... 2006 (9 % change Like-for-like ... months) months) ...
... for Applied Nanoionics (CANi) has a new take on old ... battery life of consumer electronics from digital cameras to laptops. ... and compatible with just about anything currently on the market. ... way for this memory to be made at essentially zero ...
... to $2.25 to $2.35., ST. LOUIS, Oct. 23 , HIGHLIGHTS:, ... comparable periods in 2006):, -- Strongest Quarterly Sales Growth in ... on prior quarters, performance, with reported quarterly ... high sales achieved in Q2 2007. ...
Cached Biology Technology:Essilor's 2007 Third-Quarter Report 2Essilor's 2007 Third-Quarter Report 3Essilor's 2007 Third-Quarter Report 4ASU researchers improve memory devices using nanotech 2ASU researchers improve memory devices using nanotech 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... get medicine into the brain when treating patients with neurological ... out and therefore the brains of neurological patients fight a ... help the patients. The problem is the so-called ... travelling from the blood into the brain. "The barrier ...
... bomb, Niels Bohr* worked tirelessly to promote a world ... relevant in a world where internet surveillance and the ... raise questions about not just openness but also the ... the celebrations of the 100th anniversary of Bohr,s atomic ...
... 2013 A technology-driven concept, a safe city ... and better use of intelligence. The four pillars ... technology, multi-agency collaboration, shared command & control, and ... offer a developed environment, assurance of safety for ...
Cached Biology News:Sheep's mucosa shows the way to more effective medicine for severe neurological diseases 2Sheep's mucosa shows the way to more effective medicine for severe neurological diseases 3International Niels Bohr Conference: An open world 2Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 2Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 3Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 4Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 5
... Clone/PAD: ZMD.473. Immunogen: Synthetic peptide ... the mouse junctophilin-2. Specificity: Specific ... Mouse (positive controls: mouse skeletal muscle ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: